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The MDAR framework establishes a minimum set of requirements in transparent reporting applicable to studies in the life sciences 
(see Statement of Task: doi:10.31222/osf.io/9sm4x.). The MDAR checklist is a tool for authors, editors and others seeking to adopt 
the MDAR framework for transparent reporting in manuscripts and other outputs.   Please refer to the MDAR Elaboration 







Antibodies Yes  (indicate where provided: page no/section/legend) n/a 
Rabbit anti-GFP antibody, Abcam, catalogue 
ab290;  
Goat horseradish peroxidase (HRP)-conjugated 
anti-rabbit antibody, Abcam, catalogue ab205718;  
Mouse anti-HA antibody, Sigma, catalogue H9658;  
Rabbit horseradish peroxidase (HRP)-conjugated 
anti-mouse antibody (Sigma, catalogue A9044). 
Supplementary Materials/Materials and 
Methods/Co-Immunoprecipitation (Co-IP); 
ChIP-seq and data analysis 
 
   
Cell materials Yes  (indicate where provided: page no/section/legend) n/a 
Cell lines: Provide species information, strain. 
Provide accession number in repository OR 
supplier name, catalog number, clone number, OR 
RRID 
 n/a 
Primary cultures: Provide species, strain, sex of 
origin, genetic modification status. 
 n/a 
   
Experimental animals Yes  (indicate where provided: page no/section/legend) n/a 
Laboratory animals: Provide species, strain, sex, age, 
genetic modification status. Provide accession number in 
repository OR supplier name, catalog number, clone 
number, OR RRID 
 
 n/a 
Animal observed in or captured from the field: 
Provide species, sex and age where possible 
 n/a 
Model organisms: Provide Accession number in 
repository (where relevant) OR RRID 
 n/a 
   
Plants and microbes Yes  (indicate where provided: page no/section/legend) n/a 
Plants: Arabidopsis thaliana Col-0 ecotype 
 
Supplementary Materials/Materials and 
Methods/Plant materials and growth conditions 
 
Microbes:  
Escherichia coli DH5α 
Agrobacterium tumefaciens GV3101 
 
Supplementary Materials/Materials and 
Methods/ 





   
Human research participants Yes  (indicate where provided: page no/section/legend) n/a 
Identify authority granting ethics approval (IRB or 




Provide statement confirming informed consent 
obtained from study participants. 
 
 n/a 







Study protocol Yes  (indicate where provided: page no/section/legend) n/a 
For clinical trials, provide the trial registration 




   
Laboratory protocol Yes  (indicate where provided: page no/section/legend) n/a 
RNA fluorescence in situ hybridisation 
 
 
DOI: 10.1104/PP.19.00980  
   
Experimental study design (statistics details) Yes  (indicate where provided: page no/section/legend) n/a 
State whether and how the following have 
been done, or if they were not carried out. 
  













Sample definition and in-laboratory 
replication 
Yes  (indicate where provided: page no/section/legend) n/a 
State number of times the experiment was 
replicated in laboratory 
Yes. Supplementary Materials/Materials and 
Methods/Page 3, 4, 5, 6 
 
Define whether data describe technical or 
biological replicates 
Yes. Figure legend (Figs. 2, 4, S4, S15) 
 
 
   
Ethics Yes  (indicate where provided: page no/section/legend) n/a 
Studies involving human participants: State 
details of authority granting ethics approval 
(IRB or equivalent committee(s), provide 
reference number for approval.  
 n/a 
Studies involving experimental animals: State 
details of authority granting ethics approval 
(IRB or equivalent committee(s), provide 
reference number for approval. 
 n/a 
Studies involving specimen and field 
samples: State if relevant permits obtained, 
provide details of authority approving study; 
if none were required, explain why. 
 n/a 
   
Dual Use Research of Concern (DURC) Yes  (indicate where provided: page no/section/legend) n/a 
If study is subject to dual use research of 
concern, state the authority granting 









Attrition Yes  (indicate where provided: page 
no/section/legend) 
n/a 
State if sample or data point from the analysis is 
excluded, and whether the criteria for exclusion were 
determined and specified in advance. 
 n/a 
For ChIP-seq analysis, the genes that appear only one 
time in three replicates were excluded.  
Supplementary Materials/Materials and 
Methods/ChIP-seq and data analysis 
 
   
Statistics Yes  (indicate where provided: page 
no/section/legend) 
n/a 
Describe statistical tests used and justify choice of 
tests. 
 
Yes. Figure legend (Figs. 1, 3, 4, S1, S3, S10, S13)  
   
Data Availability Yes  (indicate where provided: page 
no/section/legend) 
n/a 
State whether newly created datasets are available, 
including protocols for access or restriction on 
access. 
Ye . Mai  t xt/Data and materials availability  
If data are publicly available, provide accession 
number in repository or DOI or URL. 
Gene Expression Omnibus, accession number: 
GSE144049 
 
If publicly available data are reused, provide 
accession number in repository or DOI or URL, where 
possible. 
DOI: 10.1111/j.1365-313X.2004.02319.x  
   
Code Availability Yes  (indicate where provided: page 
no/section/legend) 
n/a 
For all newly generated code and software essential 
for replicating the main findings of the study: 
  
R (version 3.5.2)  https://www.r-project.org  
MorphoGraphX  https://www.mpipz.mpg.de/MorphoGraphX  
Fiji – ImageJ software https://fiji.sc https://fiji.sc  
FastQC  www.bioinformatics.babraham.ac.uk/projects/fastq  
ShinyGO http://bioinformatics.sdstate.edu/go/  
Picard tools  https://github.com/broadinstitute/picard  
MEME tool  http://meme-suite.org/tools/meme  




Adherence to community standards Yes  (indicate where provided: page 
no/section/legend) 
n/a 
MDAR framework recommends adoption of 
discipline-specific guidelines, established and 
endorsed through community initiatives. Journals 
have their own policy about requiring specific 
guidelines and recommendations to complement 
MDAR.  
  
State if relevant guidelines (eg., ICMJE, MIBBI, 
ARRIVE) have been followed, and whether a checklist 
(eg., CONSORT, PRISMA, ARRIVE) is provided with 
the manuscript.  
 n/a 
 
 
